Study of ALPN-101 in Subjects With Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease

2020 ◽  
Author(s):  
Keyword(s):  
Graft Versus Host Disease ◽  
Steroid Resistant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory ◽  
Acute Graft

scholarly journals Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease

2002 ◽  
Vol 8 (4) ◽  
pp. 206-212 ◽  
Author(s):  
Terry Furlong ◽  
Wendy Leisenring ◽  
Rainer Storb ◽  
Claudio Anasetti ◽  
Frederick R Appelbaum ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Ultraviolet A ◽  
Steroid Resistant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

scholarly journals Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

2001 ◽  
Vol 27 (10) ◽  
pp. 1059-1064 ◽  
Author(s):  
H Khoury ◽  
A Kashyap ◽  
DR Adkins ◽  
RA Brown ◽  
G Miller ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Steroid Resistant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Blood ◽  
2004 ◽  
Vol 104 (4) ◽  
pp. 1224-1226 ◽  
Author(s):  
Vincent T. Ho ◽  
David Zahrieh ◽  
Ephraim Hochberg ◽  
Eileen Micale ◽  
Jesse Levin ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Phase 1 ◽  
Interleukin 2 ◽  
Maximum Tolerated Dose ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
Denileukin Diftitox ◽  
Steroid Refractory ◽  
Acute Graft

Abstract Denileukin diftitox (Ontak), a recombinant protein composed of human interleukin 2 (IL-2) fused to diphtheria toxin, has selective cytotoxicity against activated lymphocytes expressing the high-affinity IL-2 receptor. We conducted a phase 1 study of denileukin diftitox in 30 patients with steroid refractory acute graft-versus-host disease (GVHD). Seven patients received 9 μg/kg intravenously on days 1 and 15; 18 received 9 μg/kg intravenously on days 1, 3, 5, 15, 17, and 19; and 5 received 9 μg/kg intravenously on days 1 to 5 and 15 to 19. Hepatic transaminase elevation was the dose-limiting toxicity (DLT), and dose level 2 was the maximum tolerated dose (MTD). Overall, 71% of patients responded with complete resolution (12 of 24; 50%) or partial resolution (5 of 24; 21%) of GVHD. Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD. (Blood. 2004;104:1224-1226)

scholarly journals Bortezomib for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

2012 ◽  
Vol 18 (2) ◽  
pp. S370 ◽  
Author(s):  
J.L. Wagner ◽  
B. Mookerjee ◽  
J.E. Filicko-O'Hara ◽  
D.A. Grosso ◽  
N. Flomenberg
Keyword(s):  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document